Brought to you by

Eisai buys AkaRx; gets thrombocytopenia candidate
01 Apr 2016
Executive Summary
Exercising an option it inherited through a prior deal, Japan's Eisai Co. Ltd. will pay $255mm to buy privately held AkaRx (blood, cancer, and immunology therapies).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com